Acute Leukemias in Children with Down Syndrome

Greaves, 2005, In utero origins of childhood leukaemia, Early Hum Dev, 81, 123, 10.1016/j.earlhumdev.2004.10.004 Roizen, 2003, Down's syndrome, Lancet, 361, 1281, 10.1016/S0140-6736(03)12987-X Krivit, 1956, The simultaneous occurrence of leukemia and mongolism; report of four cases, AMA J Dis Child, 91, 218, 10.1001/archpedi.1956.02060020220002 Hasle, 2000, Risks of leukaemia and solid tumours in individuals with Down's syndrome, Lancet, 355, 165, 10.1016/S0140-6736(99)05264-2 Hitzler, 2005, Origins of leukaemia in children with Down syndrome, Nat Rev Cancer, 5, 11, 10.1038/nrc1525 Li, 2005, Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1, Nat Genet, 37, 613, 10.1038/ng1566 Massey, 2006, A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): a Children's Oncology Group (COG) study POG-9481, Blood, 107, 4606, 10.1182/blood-2005-06-2448 Al Kasim, 2002, Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study, J Pediatr Hematol Oncol, 24, 9, 10.1097/00043426-200201000-00004 Vyas, 2006, Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis, Early Hum Dev, 82, 767, 10.1016/j.earlhumdev.2006.09.016 Vyas, 2007, Molecular insights into Down syndrome-associated leukemia, Curr Opin Pediatr, 19, 9, 10.1097/MOP.0b013e328013e7b2 Whitlock, 2005, Clinical characteristics and outcome of children with down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study, Blood, 106, 4043, 10.1182/blood-2003-10-3446 Bassal, 2005, Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952, Pediatr Blood Cancer, 44, 21, 10.1002/pbc.20193 Creutzig, 2005, AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity, Leukemia, 19, 1355, 10.1038/sj.leu.2403814 Gamis, 2003, Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891, J Clin Oncol, 21, 3415, 10.1200/JCO.2003.08.060 Tunstall-Pedoe, 2006, Trisomy 21 expands the megakaryocyte-erytroid progenitor compartment in human fetal liver—implications for Down syndrome AMKL, Blood, 108, 170a, 10.1182/blood.V108.11.563.563 Henry, 2007, Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system, Am J Med Genet A, 143, 42, 10.1002/ajmg.a.31442 Widness, 1994, Elevated erythropoietin levels in cord blood of newborns with Down's syndrome, Biol Neonate, 66, 50, 10.1159/000244089 Kivivuori, 1996, Peripheral blood cell counts in infants with Down's syndrome, Clin Genet, 49, 15, 10.1111/j.1399-0004.1996.tb04318.x De Hingh, 2005, Intrinsic abnormalities of lymphocyte counts in children with Down syndrome, J Pediatr, 147, 744, 10.1016/j.jpeds.2005.07.022 Weijerman ME, Van Furth AM, Vonk-Noordegraaf A, et al. Prevalence, neonatal characteristics and first year mortality of Down syndrome: a national study. J Pediatr, in press. Pine, 2007, Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome, Blood, 110, 2128, 10.1182/blood-2007-01-069542 Heald, 2007, Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome, Nat Clin Pract Oncol, 4, 433, 10.1038/ncponc0876 Muramatsu, 2006, A retrospective analysis of 70 cases of transient leukemia in neonates with Down syndrome, Blood, 108, 301b, 10.1182/blood.V108.11.4864.4864 Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199 Hasle, 2003, A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases, Leukemia, 17, 277, 10.1038/sj.leu.2402765 Creutzig, 1996, Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group, Leukemia, 10, 1677 Lange, 1998, Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891, Blood, 91, 608 Gamis, 2006, Outcome of Down syndrome children with acute myeloid leukemia (AML) or myelodysplasia (MDS) treated with a uniform prospective trial—initial report of the COG trial A2971, Blood, 108, 9a, 10.1182/blood.V108.11.15.15 Zeller, 2005, Acute leukaemia in children with Down syndrome: a population-based Nordic study, Br J Haematol, 128, 797, 10.1111/j.1365-2141.2005.05398.x Gamis, 2005, Acute myeloid leukemia and Down syndrome evolution of modern therapy—state of the art review, Pediatr Blood Cancer, 44, 13, 10.1002/pbc.20207 Ravindranath, 1992, Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498, Blood, 80, 2210, 10.1182/blood.V80.9.2210.2210 Lie, 1996, Br J Haematol, 94, 82, 10.1046/j.1365-2141.1996.d01-1761.x Ravindranath, 2003, Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy, J Clin Oncol, 21, 3385, 10.1200/JCO.2003.05.086 Creutzig, 2006, Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98, J Clin Oncol, 24, 4499, 10.1200/JCO.2006.06.5037 Zwaan, 2002, Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells, in children with and without Down syndrome, Blood, 99, 245, 10.1182/blood.V99.1.245 Taub, 1997, Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin, Leukemia, 11, 1594, 10.1038/sj.leu.2400747 Frost, 2000, Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?, Leukemia, 14, 943, 10.1038/sj.leu.2401753 Yamada, 2001, Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome, Int J Hematol, 74, 428, 10.1007/BF02982087 Taub, 2005, Down syndrome, drug metabolism and chromosome 21, Pediatr Blood Cancer, 44, 33, 10.1002/pbc.20092 Taub, 1996, Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia, Blood, 87, 3395, 10.1182/blood.V87.8.3395.bloodjournal8783395 Taub, 1999, Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin, Blood, 94, 1393 Taub, 2000, Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome, Cancer Res, 60, 6421 Ge, 2004, The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines, Cancer Res, 64, 728, 10.1158/0008-5472.CAN-03-2456 Al Ahmari, 2006, Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome, Br J Haematol, 133, 646, 10.1111/j.1365-2141.2006.06097.x Abildgaard, 2006, Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature, Ann Hematol, 85, 275, 10.1007/s00277-005-0045-5 Hasle H, Niemeyer C, O'Marcaigh A, et al. Myeloid leukemia in children 4 years or older with Down syndrome. A BFM, DCOG, MRC, NOPHO collaborative study. [abstract]. Presented at the 5th Bi-annual Symposium on Childhood Leukemia. Noordwijkerhout, the Netherlands, April 30–May 2, 2006. Pine, 2005, GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome, Leuk Res, 29, 1353, 10.1016/j.leukres.2005.04.007 Hasle, 2006, WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder, Leuk Res, 30, 543, 10.1016/j.leukres.2005.09.010 Dördelmann, 1998, Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group, Leukemia, 12, 645, 10.1038/sj.leu.2400989 Möricke A, Zimmermann M, Schwarz C, et al. Excellent event-free survival despite higher incidence of treatment related toxicity and mortality in Down syndrome patients with ALL as compared to patients without Down syndrome: data from the ALL-BFM 2000 trial [abstract]. Presented at the 5th Bi-annual Symposium on Childhood Leukemia. Noordwijkerhout, the Netherlands, April 30–May 2, 2006. Pui, 1993, Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia, J Clin Oncol, 11, 1361, 10.1200/JCO.1993.11.7.1361 Chessells, 2002, Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia Working Party, Leukemia, 16, 776, 10.1038/sj.leu.2402468 Lanza, 1997, The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occuring in children with Down syndrome, Leukemia, 11, 820, 10.1038/sj.leu.2400651 Steiner, 2005, Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome, Pediatr Hematol Oncol, 22, 229, 10.1080/08880010590921603 Garré, 1987, Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia, J Pediatr, 111, 606, 10.1016/S0022-3476(87)80131-2 Whitlock, 2006, Down syndrome and acute lymphoblastic leukaemia, Br J Haematol, 135, 595, 10.1111/j.1365-2141.2006.06337.x Becton, 2006, Randomized use of Cyclosporin A (CSA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group study 9421, Blood, 107, 1315, 10.1182/blood-2004-08-3218 O'Brien, 2006, Excessive cardiotxocity despite excellent leukemia-free survival for pediatric patients with Down syndrome and acute myeloid leukemia: results from POG (Pediatric Oncology Group) protocol 9421, Blood, 108, 168a Creutzig, 2007, Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML, Pediatr Blood Cancer, 48, 651, 10.1002/pbc.21105 Cantor, 2005, GATA transcription factors in hematologic disease, Int J Hematol, 81, 378, 10.1532/IJH97.04180 Wechsler, 2002, Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome, Nat Genet, 32, 148, 10.1038/ng955 Kuhl, 2005, GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1, Mol Cell Biol, 25, 8592, 10.1128/MCB.25.19.8592-8606.2005 Muntean, 2005, Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development, Blood, 106, 1223, 10.1182/blood-2005-02-0551 Hitzler, 2003, GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome, Blood, 101, 4301, 10.1182/blood-2003-01-0013 Mundschau, 2003, Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis, Blood, 101, 4298, 10.1182/blood-2002-12-3904 Rainis, 2003, Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21, Blood, 102, 981, 10.1182/blood-2002-11-3599 Groet, 2003, Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder, Lancet, 361, 1617, 10.1016/S0140-6736(03)13266-7 Xu, 2003, Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome, Blood, 102, 2960, 10.1182/blood-2003-02-0390 Ahmed, 2004, Natural history of GATA1 mutations in Down syndrome, Blood, 103, 2480, 10.1182/blood-2003-10-3383 Shimada, 2004, Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome, Blood, 103, 366, 10.1182/blood-2003-09-3219 Taub, 2004, Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome, Blood, 104, 1588, 10.1182/blood-2004-04-1563 Deguchi, 2002, Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML, Leukemia, 16, 740, 10.1038/sj.leu.2402500 Hollanda, 2006, An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis, Nat Genet, 38, 807, 10.1038/ng1825 De Vita, 2007, Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome, Br J Haematol, 137, 337, 10.1111/j.1365-2141.2007.06574.x Klusmann, 2007, Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome, Leukemia, 21, 1584, 10.1038/sj.leu.2404694 Kiyoi, 2007, JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults, Leukemia, 21, 574, 10.1038/sj.leu.2404527 Walters, 2006, Activating alleles of JAK3 in acute megakaryoblastic leukemia, Cancer Cell, 10, 65, 10.1016/j.ccr.2006.06.002 Norton, 2007, Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome, Blood, 110, 1077, 10.1182/blood-2007-03-080374 Mercher, 2006, JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model, Blood, 108, 2770, 10.1182/blood-2006-04-014712 Bourquin, 2006, Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling, Proc Natl Acad Sci USA, 103, 3339, 10.1073/pnas.0511150103 Marcucci, 2005, Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study, J Clin Oncol, 23, 9234, 10.1200/JCO.2005.03.6137 Rainis, 2005, The proto-oncogene ERG in megakaryoblastic leukemias, Cancer Res, 65, 7596, 10.1158/0008-5472.CAN-05-0147 Izraeli, 2007, Trisomy of chromosome 21 in leukemogenesis, Blood Cells Mol Dis, 39, 156, 10.1016/j.bcmd.2007.04.004